Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma
Mendez J, Cohen A, Eckenstein M, Jensen R, Burt L, Salzman K, Chamberlain M, Hsu H, Hutchinson M, Iwamoto F, Ligon K, Mrugala M, Pelayo M, Plotkin S, Puduvalli V, Raizer J, Reardon D, Sterba M, Walbert T, West B, Wong E, Zhang C, Colman H. Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology Advances 2024, vdae202. DOI: 10.1093/noajnl/vdae202.Peer-Reviewed Original ResearchMedian overall survivalRadiation therapyAdjuvant TMZTumor microenvironmentRecommended phase 2 doseModified intention-to-treat populationIntention-to-treat populationPhase 1b/2 studyPhase 1b/2 trialPhase 2 doseProgression-free survivalNewly diagnosed glioblastomaInhibitor of CSF1RMultiple dose levelsPhase 2 patientsDose escalationMedian survivalDiagnosed GBMOverall survivalOpen-labelStudy regimensTreatment resistanceGlioma modelRP2DHistorical controls
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply